Medeon Biodesign, Inc. (TPEX:6499)
Taiwan · Delayed Price · Currency is TWD 82.80
+1.70 (2.10%)
May 8, 2026, 1:30 PM CST
Medeon Biodesign Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -668.06 | -805.51 | -1,205 | -433.76 | 2,078 |
Depreciation & Amortization | 105.37 | 96.69 | 93.62 | 61.77 | 58.02 |
Other Amortization | 1.99 | 1.98 | 2.05 | 2.03 | 0.99 |
Loss (Gain) From Sale of Assets | - | - | 13.01 | - | - |
Loss (Gain) From Sale of Investments | -1.72 | 2.28 | 399.15 | -0.68 | -2,507 |
Loss (Gain) on Equity Investments | - | - | -13.54 | -47.69 | -19.66 |
Stock-Based Compensation | 13.68 | 9.73 | 15.69 | 3.11 | 5.95 |
Provision & Write-off of Bad Debts | 0.07 | 13.41 | 0.58 | - | -0.36 |
Other Operating Activities | -50.48 | -145.65 | -89.68 | -76.96 | -2,607 |
Change in Accounts Receivable | -0.95 | -9.47 | -9.99 | 5.3 | 39.65 |
Change in Inventory | 9.26 | -23.33 | -0.71 | -4.4 | -10.04 |
Change in Accounts Payable | -4.45 | 6.64 | 1.42 | 2.87 | 4.42 |
Change in Unearned Revenue | 3.42 | 1.41 | 2.25 | 0.21 | -8.18 |
Change in Other Net Operating Assets | -37.28 | 19.18 | 35.7 | 26.86 | 36.56 |
Operating Cash Flow | -629.14 | -832.67 | -755.08 | -461.34 | -293.38 |
Capital Expenditures | -16.47 | -74.3 | -55.29 | -140.57 | -8.32 |
Cash Acquisitions | - | - | - | -165.89 | 4.21 |
Divestitures | - | - | - | - | 450.92 |
Sale (Purchase) of Intangibles | -0.41 | -0.47 | -0.52 | -0.15 | -0.7 |
Investment in Securities | -4.78 | 209.92 | 1,643 | 552.91 | -535.92 |
Other Investing Activities | 0.16 | 0.06 | 8.64 | 17.13 | -0.83 |
Investing Cash Flow | -21.5 | 135.21 | 1,596 | 263.44 | -90.64 |
Long-Term Debt Repaid | -52.89 | -50.53 | -47.89 | -29.17 | -17.4 |
Total Debt Repaid | -52.89 | -50.53 | -47.89 | -29.17 | -17.4 |
Net Debt Issued (Repaid) | -52.89 | -50.53 | -47.89 | -29.17 | -17.4 |
Issuance of Common Stock | 3.77 | 3.85 | 0.23 | - | 10.1 |
Common Dividends Paid | - | - | -43.82 | -73.03 | - |
Other Financing Activities | 717.11 | - | 0.91 | 1.05 | 3.4 |
Financing Cash Flow | 667.98 | -46.68 | -90.57 | -101.16 | -3.9 |
Foreign Exchange Rate Adjustments | -9.94 | 19.55 | 4.09 | 47.64 | -4.89 |
Net Cash Flow | 7.41 | -724.59 | 754.07 | -251.42 | -392.81 |
Free Cash Flow | -645.61 | -906.97 | -810.36 | -601.91 | -301.69 |
Free Cash Flow Margin | -153.93% | -309.75% | -412.90% | -201.77% | -437.51% |
Free Cash Flow Per Share | -6.99 | -9.84 | -8.80 | -6.54 | -3.28 |
Cash Interest Paid | 3.64 | 5.56 | 6.64 | 4.6 | 1.55 |
Cash Income Tax Paid | 2.31 | 86.81 | 59.94 | 69.21 | 4.35 |
Levered Free Cash Flow | -383.52 | -561.07 | -455.87 | -416.46 | -89.12 |
Unlevered Free Cash Flow | -381.22 | -557.6 | -451.72 | -413.2 | -88.48 |
Change in Working Capital | -29.99 | -5.59 | 28.67 | 30.84 | 62.4 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.